Caryn Domenici Belisle, RPh, Alka Patel, PharmD

The FDA approved Edarbi (azilsartan medoxomil), a new angiotensin receptor blocker, for the treatment of hypertension in adults.

Pradaxa (dabigatran etexilate) is the first oral direct thrombin inhibitor to be approved by the FDA.

Vimovo (naproxen and esomeprazole magnesium) delayed-released tablets, marketed by AstraZeneca and Pozen Inc, are FDA approved for the symptomatic relief of arthritic conditions.